EMA and the Netherlands Finalize Seat Agreement

EMA and its new host country have finalized the terms of the agency’s relocation to Amsterdam.
Apr 24, 2018
By BioPharm International Editors

On April 24, 2018, the European Medicines Agency (EMA) announced that the text for the Seat Agreement between the agency and the Netherlands has been finalized. The agreement describes how EMA will be treated by the Dutch government when EMA relocates to Amsterdam. The agency also announced that the Dutch Council of Ministers had agreed to sign the agreement on April 13. The agreement will be signed after the legislative process on the relocation is completed by the European Council, the European Parliament, and the European Commission.

According to EMA, the Seat Agreement allows EMA to function independently in the Netherlands. Similar agreements apply to other EU agencies located in the Netherlands.

“As this transition needs to be supported by EMA staff in the Netherlands, a timely signing of the agreement would make sure that EMA staff and their families have clarity on their treatment and can settle in the Netherlands. This is especially important for staff who want to move before the start of the next school year,” the agency stated in a press release.

Source: EMA

 

native1_300x100
lorem ipsum